InsidersTradesSigma
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
3
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the full record of transactions filed by Greene Barry E, Chairman & CEO. Officer active across 2 companies, notably Sage Therapeutics, Inc.. In total, 7 reports have been published. Split: 3 buys · 0 sell. Total volume traded: €1.8m. Activity tracked since 16 June 2021. The latest transaction was disclosed on 10 April 2025 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Greene Barry E
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations7 total
46,940 sharesCommon StockSEC:0000950170-25-100636:0
19,964 shares0Common StockSEC:0001562180-25-003112:0
50,400 shares0Common StockSEC:0001562180-24-006090:0
14,500 shares@ US$34.484316.4% of flowCommon StockSEC:0001562180-22-007667:0
Canonical exit: 8 Feb 2023 (T+90)
7,576 shares@ US$1.485100.0% of flowCommon StockSEC:0001209191-22-045718:0
23,640 shares@ US$43.149548.6% of flowCommon StockSEC:0001562180-21-005226:0
Canonical exit: 3 Nov 2021 (T+90)
8,800 shares@ US$56.321323.3% of flowCommon StockSEC:0001562180-21-004342:0
Canonical exit: 14 Sept 2021 (T+90)
7 of 7 declarations
About Greene Barry E
Barry E. Greene is the President and CEO of Sage Therapeutics, Inc. He leads the company with a focus on innovation in healthcare. Under his leadership, Sage Therapeutics is committed to developing innovative treatments for patients.
